RESUMO

Continuous oral pamidronate (APD), 1000 mg/day, was administered to 14 patients with rheumatoid arthritis. A control group of 13 patients with similar conditions received placebo under a double blind randomized study design. Periarticular erosion scores were significantly higher in the control group after 12 months treatment. This was attributed to a deterioration in this group rather than to an improvement in the APD treated one. By contrast, intraarticular narrowing score was not influenced by APD. Tolerance to oral APD was acceptable in all patients.

Assuntos

Artrite Reumatoide/diagnóstico por imagem , Difosfonatos/administração & dosagem , Administração Oral , Adulto , Artrite Reumatoide/tratamento farmacológico , Cartilagem Articular/diagnóstico por imagem , Método Duplo-Cego , Esquema de Medicação , Feminino , Pé/diagnóstico por imagem , Mãos/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Pamidronato , Radiografia , Índice de Gravidade de Doença